In early 2010, Foregen, an Italian non-profit lobbying organization dedicated to finding interested research groups for the purposes of regrowing the human male foreskin using the regenerative capabilities of the extracellular matrix, in the hopes of eventually being able to provide regeneration to circumcised men, was founded. Unable to do so, Foregen transitioned to a non-profit, dependent upon charitable donations to accomplish its research, with its own facilities. A clinical trial had been scheduled for late 2010, before it transitioned into its own research organization, but there were insufficient donations to follow through. The goal was reached in June 2012 and they managed to obtain a laboratory and cooperation from biochemists and regenerative medicine experts. Results from their first clinical trial, decellurizing bull foreskins to create the extracellular matrix, were released in February 2013 and as of March 2018, had completed trials on cadaver human foreskins, which was published in 2017, and was in the process of peer review as of 2018. Clinical trials on human subjects might be achieved by the end of 2021.